Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2025

Conditions

CD7+ Acute LeukemiaCD7+ Lymphoma

Interventions

BIOLOGICAL

anti-CD7 CAR-T

Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion

Trial Locations (1)

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER